Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors
Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced Katerina Leftheris, Ph.D. has joined its Board of Directors. Katerina’s appointment as a Director forms part of the Company’s ongoing strategy to expand its internal therapeutics pipeline for drug targets identified using its 3D multi-omics platform.
Enhanced Genomics Extends Series A Funding to USD $19 Million to Drive Development of Therapeutics Pipeline
Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has completed a financing round, extending its total Series A funding to $19 million. Investors in this latest funding are BGF, Parkwalk and Meltwind.
Enhanced Genomics and the ALBORADA Drug Discovery Institute Partner to Accelerate Alzheimer's Drug Discovery
Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge. Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia. The partnership has already yielded novel drug targets for Alzheimer's disease, demonstrating the potential of 3D multi-omics to vastly reduce drug-discovery timelines and increase success rates across various disease areas.
Enhanced Genomics Appoints Dietrich Stephan, Ph.D. as Chair of the Board to Lead Ambitious Growth Strategy
Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced the appointment of Dietrich Stephan, Ph.D. as Chair of the Board of Directors. In this role, Dr. Stephan will lead the management team in implementing the Company’s strategic plans, including driving expansion of its internal target identification pipeline for common diseases, with an initial focus on autoimmune indications, and establishing strategic partnerships to expedite drug discovery, development, and stratification of clinical trial cohorts based on multi-omic signatures.
